A provider of manufacturing and engineering solutions, Weiss-Aug has announced a strategic rebranding initiative to streamline its organizational structure. Our new structure represents a significant step forward in aligning our brand with the value we bring to our customers.” — Elisabeth Weissenrieder-Bennis, President, Weiss-Aug EAST HANOVER, NJ, UNITED STATES, July 14, 2025 / EINPresswire.com / -- Weiss-Aug , a leading provider of advanced manufacturing and engineering solutions for over 50 y

MADISON, Wis.--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a c

OSLO, Norway, July 14, 2025 /PRNewswire/ -- The announced Extraordinary General Meeting of Navamedic ASA was held today at 13.00 CET. All items on the agenda were approved in accordance with the board of directors' proposals. A copy of the minutes from the EGM is attached to this notice and will also be made available on the Company's webpage . This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For further information, pl

Tevogen.AI’s model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing wet lab dependency, and accelerating timelines.Beyond cost savings, Tevogen.AI leadership believes AI-driven drug discovery has the potential to generate billions in top line revenues for companies who are early adopters.With virology datasets curated and alpha model created, Tevogen.AI will now apply P

LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks. As part of the agreement, STADA wil

CONCORD, Mass.--(BUSINESS WIRE)--Aviva Biopharm Inc. (Aviva Bio), a clinical-stage biopharmaceutical company developing next-generation hormone therapies for women, announced today that new preclinical data on its lead compound, d3-testosterone (d3-T), was presented at ENDO 2025, the Endocrine Society’s flagship annual meeting, on July 14th in San Francisco. Aviva Bio unveils preclinical data at #ENDO2025: d3-testosterone delivers full androgen activity and strong aromatase resistance. d3-T is d

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced that the novel findings from its research, “Using large language models for scalable extraction of real-world progression events across multiple cancer types,” have been presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Artificial Intelligence and Machine Learning, which took place July 10-12, 2025, in Montreal, QC, Canada. The research demonstrates the power of large language models

Already approved to reduce the risk of heart failure and other cardiovascular problems in patients with chronic kidney disease (CKD) associated with type 2 diabetes, Bayer's Kerendia has scored an FDA nod to treat patients with heart failure, regardless of whether they have CKD. The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has reached the market that could further alter the HF landscape.The FDA has expanded the label

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatme

HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025. O